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Abstract
Background: The gain-of-function mutation of the RET proto-oncogene, which encodes a receptor tyrosine kinase,
is strongly associated with the development of several medullary thyroid carcinomas (MTCs). Thus, the RET protein
has been explored as an excellent target for progressive and advanced MTC. In this study we have demonstrated a
therapeutic strategy for MTC by suppressing the transcription of RET proto-oncogene though the stabilization of
G-quadruplex structure formed on the promoter region of this gene using a natural product berberine.
Methods: Medullary thyroid carcinoma (MTC) TT cell line has been used to evaluate the effects of berberine on RET
expression and its downstream signaling pathways. The specificity of berberine was demonstrated by using the
papillary thyroid carcinoma TPC1 cell line, which lacks the G-quadruplex forming sequence on the RET promoter
region due to chromosomal rearrangement.
Results: Berberine suppressed the RET expression by more than 90 % in MTC TT cells at a concentration of 2.5 μg/ml
with minimal effect on the TPC1 cells. Canadine, which is a structural analogue of berberine, showed little interaction
with RET G-quadruplex and also had no effect on RET expression in MTC TT cells. The down-regulation of RET with
berberine further inhibited the cell proliferation through cell cycle arrest and activation of apoptosis in TT cells, which
was confirmed by a 2-fold increase in the caspase-3 activity and the down-regulation of cell-cycle regulatory proteins.
Conclusion: Our data strongly suggest that the G-quadruplex forming region and the stabilization of this structure
play a critical role in mediating the repressive effect of berberine on RET transcription.
Background
Medullary Thyroid Carcinoma (MTC), which originates
from the parafollicular C cells of the thyroid gland, ac-
counts for 5 % of all thyroid malignancies [1]. The MTCs
are either sporadic or inherited by a germline point muta-
tion in the RET (REarranged during transfection) proto-
oncogene as a part of multiple endocrine neoplasia type 2
(MEN2) syndrome [2, 3]. The RET proto-oncogene en-
codes a tyrosine kinase receptor on the cell surface, which
binds the members of the glial cell line-derived neuro-
trophic factor (GDNF) family of ligands via the ligand
binding site on the extra-cellular domain [4, 5]. This results
in receptor activation through the dimerization of RET and
trans-autophosphorylation of the tyrosine residues within
the intra-cellular domain [6]. The activated RET trig-
gers a cascade of internal signaling pathways, which in-
clude the MEK/ERK and PI3K/Akt that are responsible
for cell proliferation and survival respectively [7–10].
In MEN2, a point mutation in one of the cysteine resi-
dues of the intracellular domain confers a ligand-
independent dimerization of the receptor, thereby
leading to constitutive activation of the mitogenic sig-
naling pathways [11, 12]. In accordance with the piv-
otal role of RET in regulating the growth of thyroid
cancer cells in tumor development, there are clinically
available drugs for MTC therapy such as cabozantinib
and vandetanib that inhibit the tyrosine kinase activity
of RET [13–16]. Because of their potential inhibitory ef-
fects on other tyrosine kinase receptors like VEGFR, EGFR,
MET etc. [15, 16], the development of a specific RET kin-
ase inhibitor still remains challenging. Moreover, the devel-
opment of resistance against the kinase inhibitors has been
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reported in MTC due to the mutations at gatekeeper resi-
dues, which render the receptor inaccessible to drug bind-
ing [17, 18]. To overcome these challenges, we have been
developing a new strategy to turn off the transcription of
RET proto-oncogene using small molecules rather than dir-
ectly inhibiting the kinase activity of the receptor [19].
Our previous study has revealed that the G-rich sequence
of the polypurine/polypyrimidine tract in the proximal pro-
moter region of the RET gene is structurally dynamic in na-
ture [20]. This facilitates the conformational transitions
between the B-DNA and higher-order secondary structures
like G-quadruplexes under the influence of negative super-
coiling [21, 22]. The formation of G-quadruplexes involves
the stacking of two or more G-tetrads over each other and
each G-tetrad comprises a square planar arrangement of
four guanine residues joined together through Hoogsteen
hydrogen bonding [23–25]. The biological relevance of G-
quadruplexes is well established based on their formation
in the telomere region and also in the promoter region of
other oncogenes [22–26].
Furthermore, we have demonstrated that the G-
quadruplex structure is involved in down-regulating the
transcription of RET gene and that could also be con-
trolled by the stabilization of this structure using small
molecules [19]. In order to discover more drug-like mol-
ecules for our current study that exhibit transcriptional
inhibitory effect on the RET gene, we searched for com-
pounds that potentially stabilize the G-quadruplex struc-
tures in vitro. To date, several small molecules have
been characterized as G-quadruplex binding agents; and
among them, berberine is one of the most potential
compounds to stabilize these structures formed in the
telomere region and also in the promoter region of c-
Myc oncogene [27–30]. Berberine is a natural alkaloid
found in the Chinese herbal plants [31] which has an
N+-containing isoquinoline aromatic ring with a planar
conformation that allows π-stacking interactions with a
tetrad in the G-quadruplex structure [27, 28].
In this study, we investigated the interaction of berber-
ine with G-quadruplex structure formed on the RET pro-
moter region using various biophysical and biochemical
methods. We also explored the cellular effects mediated
by berberine in MTC TT cells to gain further insight in
developing berberine as a potential therapeutic agent for
MTC treatment by suppressing the RET transcription.
Methods
Chemicals
Berberine was obtained from Sigma Genosys (Woodlands,
TX, USA). Canadine and other compounds were kindly
provided from the DPT (NCI/NIH). All the compounds
were dissolved in DMSO at a final concentration of
10 mg/mL.
Materials
The 5′-FAM labelled RET-WT (5′-AGCGGGTAGGG
GCGGGGCGGGGCGGGGGCGG- 3′) and RET-MT1
(5′- AGCGGGTAGGAGCGGAGCGGGGCGGGGGCG
G-3′) oligos were purchased from Sigma Genosys
(Woodlands, TX, USA). Taq DNA polymerase was pur-
chased from Fermentas (Hanover, MD, USA).
Cell culture & media
The human medullary thyroid carcinoma cell line
(TT) was obtained from the American Type Culture
Collection (Manassas, VA, USA) and it was cultured in
DMEM 1640 medium (Cellgro, Manassas, VA, USA)
supplemented with 15 % heat inactivated fetal bovine
serum (FBS). The isogenic cell lines HEK293-WT and
HEK293-MT1, which have the luciferase reporter gene
under the control of wild type and G4 KO (harboring
two point mutations on the GC box region) RET pro-
moters respectively were generated as described in our
previous study (19). They were cultured in DMEM
1640 medium supplemented with 9 % FBS. The human
papillary thyroid carcinoma cell line (TPC1) was received
from Dr. Rebecca Schweppe (University of Colorado, Den-
ver) and was cultured in RPMI-1640 medium supple-
mented with 9 % FBS. All the cell lines were maintained
in a humidified atmosphere containing 5 % CO2 at 37 °C.
The stocks for all the cell lines were obtained from the cell
bank and were used within 6 months. We were also in-
formed that these cell lines were mycoplasma free and
were further authenticated using STR profiling.
Polymerase stop assay
The 5′-end labeling with [γ]-32P and the DNA polymerase
assay were performed as described previously [19, 20, 32].
The template DNA containing the G-quadruplex forming
sequence present at the upstream of RET promoter region
(−51 to −33 relative to transcription start site) were
annealed with the primer (P28) labeled with [γ]-32P
(Fig. 1b). The primer-annealed DNA templates were sepa-
rated from excess labeled primer or remaining template
DNA on 8 % non-denaturing polyacrylamide gel followed
by gel-purification and used in a primer extension assay
by Taq DNA polymerase.
Dimethyl Sulfate (DMS) foot printing
The DMS foot-printing with the 5′-FAM-labelled RET-
WT and RET-MT1 oligonucleotides were performed as
described in our previous study [19]. In brief, the oligo-
nucleotides that were folded into the G-quadruplex con-
formation were treated with DMS (0.2 %) for 2 min and
were then resolved on a 16 % non-denaturing gel. Each
DNA band was recovered from the gel and treated with
piperidine (10 %) following ethanol precipitation. The
cleaved products were resolved on a 16 % denaturing
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PAGE along with the sequencing markers. The gel was
dried and the fluorescence was read on a Typhoon 8600
scanner (GE Heathcare Life Sciences, Pittsburgh, PA,
USA) for analysis.
CD spectroscopy
The RET WT oligonucleotide was diluted to a strand
concentration of 5 μM in the presence of Tris–HCl buf-
fer (20 mM, pH 7.6) and 25 mM KCl and allowed to
Fig. 1 Taq DNA polymerase stop assay showing the stabilization of the RET G-quadruplex with berberine and its structural analogues. a Structures
of berberine and its analogues. b Sequence of the single-stranded template DNA annealed with the 5′-[32P] labelled primer used in DNA polymerase
stop assay. c DNA polymerase stop assay at increasing concentrations of berberine (0, 0.75, 1.5, 15 μg/ml) and its analogues (0, 0.75, 1.5,3, 15 μg/ml).
Lanes A, G, T & C represent the di-deoxy sequencing reactions with the same template, which serve as the marker to identify the exact stop site. Lane
P represents the position of the free primer on the gel
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form G-quadruplex structure by denaturing at 95 °C for
5 min and slowly cooled to room temperature. The
temperature/wavelength CD spectra were recorded using
a Jasco-810 spectrophotometer (Easton, MD, USA) using
a quartz cell of 1 mm path length and an instrument
scanning speed of 100 nm/min with a response time of
1 s over a wavelength range of 230–330 nm at increasing
temperatures from 20 °C to 90 °C. Tm was determined
by monitoring the molar ellipticity versus temperature
profiles at 262 nm using a temperature gradient of 1 °C/
min from 20 to 90 °C as described previously [19].
Reverse Transcription PCR analysis of the RET mRNA
synthesis in TT cells
The mRNA expression in TT cells following 24 and 48 h
treatments with increasing concentrations of berberine
was determined by RT-PCR as described previously [19].
The primers used for RT-PCR were as follows: RET
forward: (5′-GCAGCATTGTTGGGGGACA-3′) and
RET reverse (5′-CACCGGAAGAGGAGTAGCTG-30);
Rpl9 forward (5′ CTGAAGGGACGCACAGTTAT-3′)
and Rpl9 reverse (5′- ACGGTAGCCAGTTCCTTTCT-3′).
The RET/PTC1 expression was determined by using the
primers RET/PTC1 forward (5′- GTCGGGGGGCATTGT
CATCT-3′) and RET/PTC1 reverse (5′-AAGTTCTTCCG
AGGGAATTC-3′) as described before [33]. The PCR reac-
tions involved an initial denaturation at 95 °C for 3 min
followed by 33, 35 and 23 cycles for RET, RET/PTC1 and
Rpl9 respectively, at 95 °C for 30 s, 52 °C for 30 s and 72 °C
for 30 s on a GeneAmp PCR system 9600 (Perkin-Elmer,
Waltham, MA, USA). The PCR products were analyzed on
1.5 % agarose gel electrophoresis.
Western blotting
The whole-cell extracts were prepared and the proteins
were resolved on a 4-12 % gradient polyacrylamide SDS-
PAGE, as described previously [19]. The primary anti-
bodies used were as follows: anti-RET (# 3220), anti-pAkt
(# 9271), anti-Akt (# 9272) and anti-p-pRb (# 9307S) were
purchased from Cell signaling, Beverly, MA, USA, anti-
VEGF (sc-152), anti-Bcl-2 (sc-509), anti-c-Myc (product sc-
40), anti-pERK1/2 (sc-81492), anti-ERK1/2 (sc-271270),
anti-pMEK1/2 (sc-81503), anti-MEK1/2 (sc-81504), anti-
E2F1 (sc-56661), anti-cyclin E (sc-247) and anti-pRb (sc-50)
were purchased from Santa Cruz Biotechnology, and anti-
actin (ab8227) was purchased from Abcam. Mouse or
rabbit IgG antibodies conjugated with horseradish peroxid-
ase (HRP) (BioRad) were used as secondary antibodies. An
enhanced chemiluminescence kit (Santa Cruz Biotechnol-
ogy) was used for the detection of the luminescence.
Luciferase assay
The isogenic cell lines HEK293-WT and HEK293-MT1
were treated with different concentrations of berberine
following 24 h exposure. Luciferase expression level is
determined following the exposure to berberine using
the ONE-Glo Luciferase Assay System (Promega) follow-
ing the manufacturer’s instruction.
Chromatin Immuno-precipitation Assay (ChIP)
CHIP assay was performed to determine the binding of
SP1 and RNA pol II to the RET promoter region using
the EZ-CHIPTM (Millipore) as described previously
[19]. The immunoprecipitation was performed using
monoclonal mouse anti-SP1 (Sigma) and monoclonal
mouse anti-RNA Pol II. The binding of SP1 and RNA
pol II were quantified using RET promoter forward pri-
mer (5′- AAGCCCCACCCGGCCCAAG-3′) and re-
verse primer (5′-GACGGACACTGGGGGCGCGA-3′).
The PCR reactions involved an initial denaturation at
95 °C for 3 min followed by 40 cycles at 95 °C for 30 s,
52 °C for 30 s and 72 °C for 30 s as described previ-
ously. The PCR products were analyzed on 2 %
agarose-gel electrophoresis.
Cell viability assay
Cells were plated at a concentration of 7500 cells/well
in a 96-well plate and incubated overnight, followed by
the exposure to the compounds at wide range of con-
centrations (0 – 6.25 μg/ml) up to 24, 48 and 96 h. The
cell viability was determined by using 1 mg/ml MTT
dye as described previously [34]. The absorbance was
measured at 590 nm using a Synergy HT Multi-
detection Microplate Reader (BioTek, Winooski, VT,
USA).
Caspase-3 assay & flow cytometry
TT cells were treated with different concentrations of
berberine up to 48 h and caspase-3 activity was mea-
sured using the ApoAlert Caspase Fluorescent Assay kit
(Clonetech Laboratory, Mountain view, CA, USA) by
following the manufacturer’s protocol. FACS analysis
was performed in TT cells following the treatment with
different concentrations of berberine up to 48 h, as de-
scribed in our previous report [19].
Results
Interaction of berberine with the RET G-quadruplex
in vitro
In this study, we first examined the interactions of
berberine and its structural analogues (Fig. 1a) with
the RET G-quadruplex using DNA polymerase stop
assay. In this assay, the formation of secondary struc-
tures like the G-quadruplex on the template DNA or
the ligand-mediated stabilization of these structures is
expected to arrest the progression of Taq-DNA poly-
merase during primer extension [32]. As shown in
Fig. 1c, a dose-dependent increase in the amount of
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arrested products was observed in the presence of ber-
berine, indicating the strongest interaction of this
compound among its analogues with the RET G-
quadruplex.
To further validate the stabilization of the RET G-
quadruplex with berberine, CD spectroscopic analysis
was performed for the RET-WT sequence in the ab-
sence and presence of berberine. First, we determined
whether the binding of berberine changes the structural
configuration of the RET G-quadruplex structure by
monitoring the CD spectra in the absence and presence
of increasing concentrations of berberine. As shown in
the Fig. 2a the titration of RET-WT sequence (5 μM)
with increasing concentrations of berberine did not
affect the peak at 262 nm suggesting that berberine does
not alter the parallel configuration of the RET G-
quadruplex structure [35]. Next, we determined whether
the binding of berberine stabilizes the G-quadruplex
structure by monitoring the CD spectra in the absence
and presence of berberine (5 Equivalents) at increasing
temperatures. As shown in Fig. 2b, the intensity of the
maximum peak at 262 nm gradually decreased as the
temperature increases from 20 °C to 90 °C and a 50 % de-
crease was observed at ~72 °C, which corresponds to its
melting temperature (Tm) (Fig. 2b, c). In the presence of
berberine (5 Equivalents) the Tm was increased to ~85 °C
(Fig. 2b, c), indicating that the RET G-quadruplex could
be stabilized with berberine.
Fig. 2 CD spectroscopic studies to validate the stabilization of RET G-quadruplex with berberine. a CD titration spectra for the RET-WT (5 μM) in
the absence and presence of increasing concentrations of berberine (b) CD titration spectra for the RET-WT (5 μM) in the absence and in the presence
of berberine (5 Equivalents) with increasing temperatures from 20 °C to 90 °C. c Melting curve of the RET-WT G-quadruplex in the absence and in the
presence of berberine (5 Equivalents)
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Selective suppression of RET in TT cells by berberine
Since our in vitro studies revealed that berberine is a po-
tential small molecule that interacts with and stabilizes
the G-quadruplex structure formed on the RET pro-
moter region, we next examined the effect of berberine
on the RET expression using in vitro cell-based assays.
The MTC TT cell line was chosen in our study because
the expression of the RET proto-oncogene in this cell
line is under the control of the promoter region that
contains the G-rich sequence, which adopts G-quadruplex
structure [19]. As shown in Fig. 3a, berberine decreased
the RET gene expression by more than 50 % and 90 %
after 24 and 48 h exposure respectively at a non-toxic
concentration of 2.5 μg/ml. The RET protein expression
was also diminished based on the western blot analysis
(Fig. 3b).
To further probe whether the G-quadruplex structure
formed in the promoter region of RET gene is the intra-
cellular target for berberine, papillary thyroid carcinoma
(PTC) TPC1 cells were used. The RET/PTC1 gene ex-
pression in this cell line is under the control of the pro-
moter region of the CCD6 gene due to chromosomal
rearrangement [36–39], which lacks the G-quadruplex
forming motif. As shown in the Fig. 3c the RET/PTC1
mRNA expression was not significantly decreased in the
presence of berberine following 24 h exposure. This data
clearly suggests that the presence of G-quadruplex form-
ing sequence on the proximal promoter region of the
RET gene, plays a critical role in mediating the effect of
berberine on gene expression.
Effect of berberine on RET promoter activity
To investigate whether berberine suppresses the RET
gene expression by inhibiting its promoter activity
through G-quadruplex stabilization, two isogenic cell
lines HEK293-WT and HEK293-MT1 in which the ex-
pression of the luciferase reporter gene is under the
control of wild-type and G4 knockout (KO) mutant
RET promoter regions respectively were used [19]. As
shown in Fig. 4a, approximately 60 % decrease in the
luciferase expression was observed in both cell lines in
the presence of berberine (10 μg/ml). This suggests
that the inhibitory effect of berberine is independent
of the G-quadruplex structure formed on the RET
promoter region because the G4 KO sequence in the
HEK293-MT1 cell line is unable to form this structure
Fig. 3 Effect of berberine on RET expression in both the TT and TPC1 cell lines. a Effect of berberine on the RET mRNA expression in TT cells after
24 and 48 h treatments at various concentrations. b RET protein expression in TT cells were determined by western blotting after the 24 and
48 h exposure to increasing concentrations of berberine. c Effect of berberine on the RET/PTC1 mRNA expression in TPC1 cells was determined
following 24 h exposure with various concentrations of berberine. d Protein expression levels of VEGF and c-MYC in TT cells in the presence of
berberine at various concentrations and exposed up to 48 h
Kumarasamy et al. BMC Cancer  (2015) 15:599 Page 6 of 13
[19]. Based on this data we predicted that berberine
could be able to bind the RET-MT1 sequence on the
promoter region and might form an unknown struc-
ture, through which it inhibits RET gene promoter
activity.
To verify our prediction, we investigated the mode of
interaction of berberine with both RET-WT & RET-
MT1 G-rich sequences by DMS footprinting. DMS
footprinting is a well-known technique to determine
the guanine bases that are involved in the G-
Fig. 4 Effect of berberine on the promoter activity of the RET gene. a Effect of berberine on the luciferase expression in HEK293-WT and HEK293-
MT1 cell lines following the treatment with berberine up to 24 h. Luciferase activity in cell lysates was measured as relative luminescence units
(RLU) and normalized to the total protein content. Experiments were performed in triplicate. Error bar represent one s.d. above and below the
mean % luciferase activity. b DMS foot printing on the RET-WT G-quadruplex forming sequence in the absence and in the presence of berberine
(5 Equivalents) following 0.2 % DMS treatment (lanes C & B respectively). Purine & pyrimidine sequencing act as single base ladders to identify
the protected and cleaved guanines after piperidine treatment (lanes 1 & 2 respectively). c Schematic models for the parallel G-quadruplexes
formed by RET-WT (d) DMS foot printing on the RET-MT1 quadruplex forming sequence in the absence and in the presence of 5 equivalents of
berberine following 0.2 % DMS treatment (lanes C & B respectively). e ChIP analysis to determine the effect of berberine in recruiting the SP1 and
RNA pol II to the GC box region in the RET promoter region in TT cells following 48 h exposure at two different concentrations. Recruitment of
SP1 and Pol II to the RET proximal promoter region was assessed by PCR using RET promoter specific primers. 1 % of the input DNA was used as
internal control (Input) and isotype-matched IgG was used as a negative control for immunoprecipitation (Ig)
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quadruplex formation. The N7 positions of these gua-
nines are involved in Hoogsteen base-pairing to form
the G-tetrad and are protected from methylation by
DMS [25, 40, 41]. As shown in Fig. 4b lane C, the pat-
tern of N7-guanine methylation produced by the RET
WT sequence in the presence of 100 mM K+ is consist-
ent with two intra-molecular parallel G-quadruplexes
each containing three G-tetrads (Fig. 4c, Model 1&2).
As shown in Fig. 4b lane B, after the addition of ber-
berine (5 Equivalents), the pattern of N7-guanine
methylation is consistent with a single intra-molecular
parallel G-quadruplex as shown in the Fig. 4c (Model
1) suggesting that the binding of berberine with the
G-quadruplexes transforms them into a single con-
formation. Based on the DMS footprinting on the
RET-MT1 sequence in the absence and presence of
berberine (5 Equivalents), the guanine G22 in the G-
quadruplex/berberine complex (Fig. 4d lane B) clearly
showed an enhanced cleavage compared to the un-
bound G-quadruplex (Fig. 4d lane C). This clearly in-
dicates the interaction of berberine with the G4
knockout (KO) mutant sequence on the RET promoter
region.
To further understand the cellular mechanism through
which berberine inhibits the RET expression, a Chroma-
tin Immunoprecipitation (ChIP) assay was performed to
investigate the effect of berberine on the RET promoter
occupancy by SP1 and RNA pol II in TT cells. As shown
in Fig. 4e, the ChIP assay revealed that berberine pre-
vents the SP1 and pol II binding to the RET promoter,
suggesting that the G-quadruplex interacting agents
might possibly interfere with the transcription complex
assembly at the RET promoter region.
Effect of canadine on the RET promoter activity
Canadine is one of the analogues, which closely re-
sembles the structure of berberine [42]. However the
saturated double bonds in the isoquinoline ring might
alter its aromaticity [42], thereby interrupting it’s
binding with the G-quadruplex (Fig. 5a). The CD spec-
tra of the RET G-quadruplex at increasing tempera-
tures were obtained in the absence and presence of
canadine (5 Equivalents). As anticipated the Tm of the
RET G-quadruplex structure was not significantly in-
creased after the addition of canadine (5 Equivalents)
(Fig. 5b, c), suggesting that canadine does not stabilize
the G-quadruplex structure formed in the RET pro-
moter region.
Next, we investigated if canadine has differential effect
from berberine on the RET gene promoter activity by
measuring the luciferase expression level in the HEK293-
WT cells in the presence of various concentrations of
canadine. As shown in Fig. 5d, no significant decrease in
the luciferase level was observed even at 10 μg/ml
following 24 h exposure. The RET protein expression level
in TT cells was also not decreased after 48 h treatment
with canadine (Fig. 5e). Overall, these data suggest that
the stabilization of the G-quadruplex structure in the RET
promoter region with berberine is important in suppress-
ing the gene transcription.
Cellular effects mediated by the RET expression
Since RET is a growth factor receptor and mainly in-
volved in mediating the cell proliferation and viability,
we examined the effect of berberine on the growth of
TT cell line by MTT assay. As shown in Fig. 6a, the
viability of TT cells decreased with increasing concen-
trations of berberine and the IC50 was found to be ap-
proximately 1 μg/ml after 96 h exposure. This clearly
shows that the RET expression plays a major role in
regulating the cell proliferation and viability.
We further characterized the mechanism through
which berberine suppresses the proliferation of TT
cells by determining whether the mitogenic signaling
pathways of RET are inhibited. Following the exposure
of TT cells with berberine, the phosphorylation status
of MEK/ERK and Akt were determined, as they are
the major kinases involved in the signal transduction
pathways activated by oncogenic RET [9]. As shown in
the Fig. 6b, berberine inhibits the phosphorylation of
Akt in a dose-dependent manner whereas the phos-
phorylated MEK/ERK levels were not altered. This
suggests that the inhibition of RET expression by ber-
berine in TT cells results in the down-regulation of
the PI3k/Akt pathway.
Next, we investigated how the reduced levels of phos-
phorylated Akt contribute to the suppression of cell
proliferation by determining the effect of berberine on
the downstream targets of this pathway. Based on the
previous reports the PI3K/Akt pro-survival pathway
activates the anti-apoptotic Bcl-2, thereby preventing
the caspase-3 activation [9]. Interestingly, berberine re-
duced the Bcl-2 expression in TT cells, which in turn
showed 2.5 fold increase in the caspase-3 activity com-
pared to the untreated cells (Fig. 6c). Flow cytometry
analysis of the TT cells after 48 h incubation with dif-
ferent concentrations of berberine showed an increase
in the percentage of cells at G1 phase at 1.25 μg/ml,
indicating G1 arrest (Fig. 6d). At high concentration of
berberine (2.5 μg/ml) increase in apoptotic cells was
observed, which was represented by a higher percent-
age of TT cells in the sub-G1 phase as compared to the
untreated cells (Fig. 6d). The increase in apoptosis is
further accompanied by decrease in the percentage of
cells at both S and G2 phases, which clearly indicates
that berberine induces apoptosis in TT cells through
G1-arrest (Fig. 6d). To further confirm the cell cycle-
arrest mediated by berberine, the expression of cell-
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cycle regulatory proteins were determined. The phos-
phorylation of the retinoblastoma protein Rb at the G1
phase releases the transcription factor E2F1, which in-
turn transactivates cyclin E that is required to progress
through S phase [43]. As shown in the Fig. 6e, the
expression of the phosphorylated Rb, E2F1 and cyclin E
were reduced significantly in the presence of berberine,
which clearly indicates the cell cycle arrest.
Fig. 5 Effect of canadine on the G-quadruplex stabilization and on the RET promoter activity. a Structures of berberine and canadine. b CD titration spectra
for the RET-WT (5 μM) in the absence and in the presence of canadine (5 Equivalents) with increasing temperatures from 20 °C to 90 °C. c Melting curve of
the RET-WT G-quadruplex in the absence and in the presence of canadine (5 Equivalents). d Effect of canadine on the luciferase expression level in
HEK293-WT cell line at various concentrations after 24 h treatment. e Effect on the RET protein expression in TT cells after 48 h incubation at an increasing
concentrations of canadine
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Discussion
The main objective of our study is to highlight a thera-
peutic strategy to specifically treat MTC by silencing the
transcription of RET gene using small molecules. Al-
though the use of small interfering RNAs (siRNAs) has
been developed as a promising strategy to silence the
gene expression [44], there are several pitfalls in devel-
oping siRNAs as drug-like molecules. The siRNAs are
negatively- charged and large in size that thwart their
permeability into the plasma membrane of the target
cells and also they are highly susceptible to degradation
by the enzymes present in the extracellular region,
thereby decreasing its therapeutic potential [45]. Hence,
the use of small-molecule inhibitors that diffuse readily
into the cell membranes and suppress the gene expres-
sion overcomes these pitfalls and challenges. The tran-
scriptional inhibitory effect exerted by the formation of
the G-quadruplex structure on the RET gene promoter
region led us to stabilize this secondary structure using
small molecules to suppress the gene expression. Based
Fig. 6 Cellular effects mediated by RET expression in TT cells. a MTT assay for TT cells, treated with an increasing concentration of berberine for 96 h to
determine the cell viability. b The phosphorylation status of Akt, MEK1/2 and ERK1/2 were determined in TT cells following the exposure with different
concentrations of berberine. c The Bcl-2 and the Capsase-3 activity in TT cells were determined in the presence of increasing concentrations of berberine.
d FACS analysis of TT cells treated with various concentrations of berberine for 48 h. Data are mean +/−s.e.m of three separate experiments. e Western
Blot analysis to determine the protein expression of pRb, p-pRb, E2F1, Cyclin E in TT cells
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on the results obtained from in vitro biochemical and cell-
based assays, an isoquinoline alkaloid called berberine has
been identified as a potential small-molecule to bind and
stabilize the RET G-quadruplex. The stabilization of the G-
quadruplex structure by berberine also exerted inhibitory
effects on the RET promoter activity, which was observed
by the luciferase expression that is under the control of
RET promoter region. The ChIP assay further revealed that
berberine prevented the binding of SP1 and PolII with the
RET promoter region thereby inhibiting the transcription
of this gene. Overall, our data suggest that the cellular tar-
get for berberine might be the G-quadruplex structure
formed on the RET promoter region.
The most challenging issue in the target based drug
discovery is to address the specific interaction of a com-
pound with its target. Hence it is important to demon-
strate that the formation of the G-quadruplex structure
on the proximal promoter region of the RET gene is
strictly required to mediate the inhibitory effect of ber-
berine. To address this issue, we included the papillary
thyroid carcinoma (PTC) TPC1 cells in our study. Like
MTC, the development of PTC is also due to the consti-
tutive activation of the RET protein in a ligand inde-
pendent manner [36]. However, the gain-of-function
mutation of this protein in PTC is due to chromosomal
rearrangement of the RET kinase domain coding region
with the 5′ terminal of the coiled-coil domain contain-
ing gene 6 (CCD6) at chromosome 10q11.2 [36]. This re-
sults in a truncated fusion protein called RET/PTC1 in
which the dimerization domain of the CCD6 gene medi-
ates the formation of RET homo-dimers, followed by
phosphorylation of the tyrosine residues and activation of
the downstream signaling pathways [38]. Due to the
chromosomal inversion the RET/PTC gene is under the
control of CCD6 promoter region, which does not have
the GC box region and thus cannot form the G-
quadruplex structure. In our study, the RET/PTC1 mRNA
levels were not decreased in the presence of berberine,
suggesting that this compound is highly specific to MTC
due to the G-quadruplex forming sequence present on the
RET promoter. Although, the previous study has demon-
strated the anti-proliferative effects of berberine in TPC1
cells, the transcriptional inhibitory effect of berberine on
the RET/PTC1 gene expression was not addressed [46].
To further confirm the specificity of berberine in tar-
geting the G-quadruplex structure, we took advantage of
the structure-activity relationship that mediates the
binding with this structure. Canadine resembles the
structure of berberine but it has a tertiary amine group
due to the saturation of the double bonds in the isoqui-
noline ring, which alters its planarity due to the loss of π
electrons [42]. This disrupts the binding potential of
canadine with the G-quadruplex thereby exhibiting no
biological activity in the TT cells. This shows that the
inhibition of the RET gene in TT cells by berberine is
only due to its interaction with and stabilization of the
G-quadruplex structure.
In our study, berberine showed a selective effect on the
RET gene expression by inhibiting its transcription, with-
out significantly affecting the other major oncogenes like
c-Myc and VEGF (Fig. 3d), which also have the GC-rich
sequence on their promoter regions [40, 41]. A plausible
explanation is that the intra-cellular G-quadruplex forma-
tion is more predominant in the RET promoter region
than the other regions in the chromosome, which favors
the specific interaction of berberine. Even though berber-
ine has been shown to suppress c-MYC expression [47],
the concentration at which it is active against this onco-
gene is several fold higher than that against the RET ex-
pression. We have also shown that the disruption of the
oncogenic RET expression in TT cells in the presence of
berberine further suppressed the cell proliferation and via-
bility through the down-regulation of PI3K/Akt pathway,
which in turn activates apoptotic cell death. The MEK/
ERK pathway, which has also been known as the down-
stream signal transduction pathway was not inhibited by
berberine suggesting that either this pathway could be
governed by other growth factor receptors like VEGFR,
EGFR etc. [9, 48, 49] or prolonged exposure with berber-
ine could inhibit this pathway.
Conclusion
We have clearly demonstrated that berberine selectively
suppresses the transcription of RET proto-oncogene
through the stabilization of the G-quadruplex structure
formed on the promoter region. The downstream signal-
ing pathways that are mediated by RET activation were
also down-regulated in the presence of berberine, which
further inhibited the MTC TT cell proliferation through
cell cycle arrest and the activation of apoptosis. Hence
berberine has definite potential as a drug, based on its
diverse pharmacological properties and activities, which
could be further developed for the pre-clinical and clin-
ical studies to treat MTC patients and also be used in
combination therapy with other RET kinase inhibitors.
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